Pharmaceutical Preparations · SIC 2834

Ovid Therapeutics Inc.

OVID

Watch

Latest revenue

$0

as of 2026-03-31

Latest net income

$-17.0M

as of 2026-03-31

Net margin

as of 2026-03-31

Community sentiment

Where do you think OVID is heading?

1 month
6 months
12 months
5 years
Sign in free to vote and see community sentiment

Keep private notes on OVID — thesis, target price, catalysts to watch.

Visible only to you. Never shared. Never used to train AI.

Sign in to add your own notes

OVID vs S&P 500 · rebased to 100

-11.8% / yr 31.5 pts / yr vs S&P 500(S&P 500 +19.7% / yr) 46.5% total
Compare:

Market data

Price feed temporarily unavailable for OVID.

What this company does

AI

Item 1. BUSINESS Overview Ovid is a biopharmaceutical company that is dedicated to developing small molecule medicines for brain disorders with significant unmet need. These potential medicines targeting the central nervous system (“CNS”) are designed to potentially halt the course of brain disease by quelling neuronal hyperexcitation and alleviating the most impactful patient symptoms. We seek to address fundamental biological targets in the brain that are implicated in neuronal hyperexcitability, such as neurotransmitters and dysregulated ion channels. By mitigating excessive neuronal hyperexcitation with differentiated medicines, we believe we can unlock substantial scientific,…

AI summary unavailable — showing raw filing excerpt

Generated from OVID's filing dated 2026-03-18

Key risks

AI

Item 1A. Risk Factors An investment in our securities involves a high degree of risk. You should carefully consider the following information about these risks, together with the other information appearing elsewhere in this Annual Report on Form 10-K, including our audited consolidated financial statements and related notes hereto, before deciding to invest in our common stock. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may…

AI summary unavailable — showing raw filing excerpt

Generated from OVID's filing dated 2026-03-18

7.2
of 10

ActaClear Score

Above avg
#179 of 528 in Pharmaceutical Preparations
-0.1 · 5d
Profitability·25%
7.5
Growth·15%
6.1
Value·20%
6.0
Quality·20%
Momentum·20%
8.9

Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 10, 2026.